Frontotemporal lobar degeneration (FTLD) is one of the most common causes of early-onset
dementia and presents with early social–emotional–behavioural and/or language changes …

Increasing appreciation of the phenotypic and biological overlap between amyotrophic
lateral sclerosis (ALS) and frontotemporal dementia, alongside evolving biomarker evidence …

According to the Geroscience concept that organismal aging and age-associated diseases
share the same basic molecular mechanisms, the identification of biomarkers of age that can …

Frontotemporal dementia (FTD) therapy development is hamstrung by a lack of
susceptibility, diagnostic, and prognostic biomarkers. Blood neurofilament light (NfL) shows …

Neurofilament proteins (Nf) have been validated and established as a reliable body fluid
biomarker for neurodegenerative pathology. This review covers seven Nf isoforms, Nf light …

Neurological biomarkers are particularly valuable to clinicians as they can be used for
diagnosis, prognosis, or response to treatment. This field of neurology has evolved …

Objective Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disease
with profound unmet need. In patients carrying genetic mutations, elevations in …

Background and Objectives Elevated serum neurofilament light chain (NfL) is used to
identify carriers of genetic frontotemporal dementia (FTD) pathogenic variants approaching …

Frontotemporal dementia (FTD) is one of the most common neurodegenerative diseases,
encompassing a myriad of different, clinically distinct subtypes which all target the …

Background: Frontotemporal dementia (FTD) syndromes, mimics, phenocopy (phFTD), and
slowly progressive behavioral variant FTD (bvFTD) can be difficult to distinguish clinically …